IMBiotechnologies Ltd., (IMB) is a privately held Canadian biotechnology company whose focus is commercializing medical device products in the area of embolotherapy*. Lead products include devices for the treatment of benign and malignant tumors, with particular focus on the treatment of Uterine Fibroids, and enlarged prostates due to benign prostatic hypertropy/hyperplasia (BPH). IMB's products are unique in their ability to target specific sites using BIODEGRADABLE materials.
IMB's mission is to create and commercialize products that treat human disease and improve quality of life. Over 2 million women in the USA alone seek treatment for debilitating uterine fibroids**. 50% of men over 40 years of age have histologic prostate hyperplasia, of which 50% will have bothersome lower urinary tract symptoms (LUTS) due to BPH. This equates to over 10 million men in the USA and over 1.2 million men in Canada seeking medical attention for LUTS. IMB is committed to developing and commercializing a safe, site specific, biodegradable product to treat uterine fibroids, and eliminate the pain and suffering of millions of women worldwide.
IMB is located in Edmonton, Canada with strategic proximity to centres of scientific and clinical excellence in interventional radiology.
*Embolotherapy involves the delivery of agents such as particles, to the blood vessels feeding a tumor, using a catheter. The particles cause the blood to clot cutting off the blood supply to the tumor.
**Uterine Fibroids are benign tumors of the uterus that can grow as large as grapefruit and cause heavy periods, pain, frequent urination, bloating and reproductive problems including infertility and miscarriage.
Our Products and Opportunities
IMBIOTECHNOLOGIES LTD., is a late stage biotechnology company with near term commercialization opportunities. To learn more or receive information on investment opportunities, click here.
Learn more about our company and management team, click here.